On September 15, the Federal Trade Commission (“FTC”) and U.S. Department of Health and Human Services (“HHS”) announced an updated joint publication describing the privacy and security laws and rules that impact consumer health data.  Specifically, the “Collecting, Using, or Sharing Consumer Health Information? Look to HIPAA, the FTC Act, and the Health Breach Notification Rule” guidance provides an overview of the Health Insurance Portability and Accountability Act, as amended, and the implementing regulations issued by HHS (collectively “HIPAA”); the FTC Act; and the FTC’s Health Breach Notification Rule (“HBNR”) and how they may apply to businesses.  This joint guidance follows a recent surge of FTC enforcement in the health privacy space.  We offer below a high-level summary of the requirements flagged by the guidance.

  • HIPAA:  The guidance reminds businesses that HIPAA applies to covered entities (i.e., health plans, health care providers that conduct standard health care transactions electronically, or health care clearinghouses) and their business associates (i.e., companies that provide services that involve access to or maintenance of protected health information (“PHI”)) and provides an overview of HIPAA’s implementing regulations (i.e., the Privacy Rule, the Security Rule, and the Breach Notification Rule).  The guidance places particular emphasis on the requirement to obtain individual authorization to collect, use, or disclose PHI, or, with respect to business associates, to enter into a business associate agreement to receive PHI from a covered entity.
  • FTC Act:  The guidance reminds businesses that the FTC Act, which applies to business entities whether or not they are subject to HIPAA, prohibits misleading consumers about the use or disclosure of their health information.  At a general level, the guidance advises business to periodically review their data policies, procedures, and practices to (1) ensure consumer health data is secure, and (2) confirm any representations made to consumers about their health data are clear and conspicuous and consistent with actual practice.  In addition to these general guidelines, the guidance also contains a number of specific examples of actions that may trigger FTC Act compliance concerns.  With respect to HIPAA, the guidance flags that “if the information surrounding your HIPAA authorization is deceptive or misleading (such as by implying that to receive treatment, the consumer must agree to have their data used for advertising purposes), then that’s a violation of the FTC Act.”  The guidance also reminds businesses that they should not falsely assert HIPAA compliance, which was an issue raised in the FTC’s enforcement action against GoodRx, and should ensure that any claims about deleting personal information upon request align with the business’s actual practice.
  • HBNR:  The guidance explains that the HBNR applies to certain entities not covered by HIPAA (i.e., vendors of personal health records (“PHR”), PHR related entities, and third party service providers), including health apps and other connected devices.  The HBNR requires such entities to notify individuals, the FTC, and, in some cases, the media following a breach involving unsecured identifiable health information.  Under the HBNR, a “breach” includes not only cybersecurity incidents, but also unauthorized disclosures of consumer health information.  The guidance aligns with the FTC’s September 2021 “Statement of the Commission on Breaches by Health Apps and Other Connected Devices.”

The guidance encourages businesses offering health apps to review the FTC-HHS Mobile Health App Interactive Tool, which is a questionnaire designed to help mobile health app developers identify federal laws and regulations that may apply to their products, as well as the FTC’s best practices guidance for mobile health app developers and the HHS Office for Civil Rights’ resources for mobile health apps developers

Photo of Libbie Canter Libbie Canter

Libbie Canter represents a wide variety of multinational companies on privacy, cyber security, and technology transaction issues, including helping clients with their most complex privacy challenges and the development of governance frameworks and processes to comply with global privacy laws. She routinely supports…

Libbie Canter represents a wide variety of multinational companies on privacy, cyber security, and technology transaction issues, including helping clients with their most complex privacy challenges and the development of governance frameworks and processes to comply with global privacy laws. She routinely supports clients on their efforts to launch new products and services involving emerging technologies, and she has assisted dozens of clients with their efforts to prepare for and comply with federal and state privacy laws, including the California Consumer Privacy Act and California Privacy Rights Act.

Libbie represents clients across industries, but she also has deep expertise in advising clients in highly-regulated sectors, including financial services and digital health companies. She counsels these companies — and their technology and advertising partners — on how to address legacy regulatory issues and the cutting edge issues that have emerged with industry innovations and data collaborations.

As part of her practice, she also regularly represents clients in strategic transactions involving personal data and cybersecurity risk. She advises companies from all sectors on compliance with laws governing the handling of health-related data. Libbie is recognized as an Up and Coming lawyer in Chambers USA, Privacy & Data Security: Healthcare. Chambers USA notes, Libbie is “incredibly sharp and really thorough. She can do the nitty-gritty, in-the-weeds legal work incredibly well but she also can think of a bigger-picture business context and help to think through practical solutions.”

Photo of Anna D. Kraus Anna D. Kraus

Anna Durand Kraus advises on issues relating to the complex array of laws governing the health care industry. Her background as Deputy General Counsel to the U.S. Department of Health and Human Services (“HHS”) gives her broad experience with, and valuable insight into…

Anna Durand Kraus advises on issues relating to the complex array of laws governing the health care industry. Her background as Deputy General Counsel to the U.S. Department of Health and Human Services (“HHS”) gives her broad experience with, and valuable insight into, the programs and issues within the purview of HHS, including Medicare, Medicaid, fraud and abuse, and HIPAA privacy and security. Anna is co-chair of the firm’s Health Care Industry practice group.

Anna regularly advises clients on Medicare reimbursement matters, particularly those arising under Part B and the Part D prescription drug benefit. She also has extensive experience with the Medicaid Drug Rebate program. She assists numerous pharmaceutical and device manufacturers, health care providers, pharmacy benefit managers, and other health care industry stakeholders to navigate the challenges and opportunities presented by the Affordable Care Act.

Anna is a trusted adviser on health information privacy, security and breach notification issues, including those arising under the Health Insurance Portability and Accountability Act (“HIPAA”) and the Health Information Technology for Economic and Clinical Health (“HITECH”) Act. Her background in this area dates back to the issuance of the original HIPAA privacy regulations.

Anna’s clients depend on her to guide them through compliance with the Anti-Kickback statute, the Stark regulations, and other laws preventing fraud and abuse in the health care industry. Her deep knowledge of these laws has made her an important component of the firm’s representation of pharmaceutical companies and health care organizations under federal investigation or facing allegations under the False Claims Act. In addition, clients contemplating acquisitions in the health care sector rely on her to guide due diligence efforts.

Photo of Olivia Vega Olivia Vega

Olivia Vega provides strategic advice to global companies on a broad range of privacy, health care, and technology issues, including in technology transactions, mergers and acquisitions, and regulatory compliance. Within her practice, Olivia counsels clients on navigating the complex web of federal and…

Olivia Vega provides strategic advice to global companies on a broad range of privacy, health care, and technology issues, including in technology transactions, mergers and acquisitions, and regulatory compliance. Within her practice, Olivia counsels clients on navigating the complex web of federal and state privacy and data security laws and regulations, including on topics such as HIPAA, California’s Confidentiality of Medical Information Act, and the California Consumer Privacy Act. In addition, Olivia maintains an active pro bono practice.